CFTR chloride channel is a molecular target of the natural cancer preventive agent resveratrol Shuang Yang1

Pharmazie

Volumn 68, Issue 9, 2013, Pages 772-776

  Yu, Bo ^a   Sui, Yujie ^b   Zhang, Yaofang ^a   Wang, Xue ^a   Hou, Shuguang ^a   Ma, Tonghui ^a,b   Yang, Hong ^a  

^a LIAONING NORMAL UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENISTEIN; RESVERATROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHLORIDE TRANSPORT; COLON MUCOSA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; DRUG TARGETING; EPITHELIUM CELL; GENETIC TRANSFECTION; NONHUMAN; PATCH CLAMP; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RAT;

ANIMALS; ANTICARCINOGENIC AGENTS; CELLS, CULTURED; COLON; CYCLIC AMP; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DIFFUSION CHAMBERS, CULTURE; DNA, COMPLEMENTARY; INTESTINAL MUCOSA; PATCH-CLAMP TECHNIQUES; RATS; RATS, SPRAGUE-DAWLEY; STILBENES; TRANSFECTION;

EID: 84884732389     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2013.3548     Document Type: Article

References (34)

1. Alexander NS, Hatch N, Zhang S, Skinner D, Fortenberry J, Sorscher EJ, Woodworth BA (2011) Resveratrol has salutary effects on mucociliary transport and inflammation in sinonasal epithelium. Laryngoscope 121: 1313-1319.
2. Banales JM, Prieto J, Medina JF (2006) Cholangiocyte anion exchange and biliary bicarbonate excretion. World J Gastroenterol 12: 3496-3511. (Pubitemid 43997027)
3. Baur JA, Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5: 493-506. (Pubitemid 44136961)
4. Blumenstein I, Keseru B, Wolter F, Stein J (2005) The chemopreventive agent RES stimulates cyclic AMP-dependent chloride secretion in vitro. Clin Cancer Res 11: 5651-5656. (Pubitemid 41060845)
5. Cohn JA, Friedman KJ, Noone PG, Knowles MR, Silverman LM, Jowell PS (1998) Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med 339: 653-658. (Pubitemid 28402089)
6. de Lange DW, Verhoef S, Gorter G, Kraaijenhagen RJ, van de Wiel A, Akkerman JW (2007) Polyphenolic grape extract inhibits platelet activation through PECAM-1: an explanation for the French paradox. Alcohol Clin Exp Res 31: 1308-1314. (Pubitemid 47063132)
7. El-Mowafy AM, Alkhalaf M (2003) Resveratrol activates adenylyl-cyclase in human breast cancer cells: A novel, estrogen receptor-independent cytostatic mechanism. Carcinogenesis 24: 869-873. (Pubitemid 36748902)
8. El-Mowafy AM, Alkhalaf M, Jaffal SM (2007) Nongenomic activation of the GC-A enzyme by resveratrol and estradiol downstream from membrane estrogen receptors in human coronary arterial cells. Nutr Metab Cardiovasc Dis 17: 508-516. (Pubitemid 47176860)
9. El Mowafy AM, White RE (1999) Resveratrol inhibits MAPK activity and nuclear translocation in coronary artery smooth muscle: reversal of endothelin-1 stimulatory effects. FEBS Lett 451: 63-67. (Pubitemid 29236173)
10. Frémont L (2000) Biological effects of resveratrol. Life Sci 66: 663-673.
11. French PJ, Bijman J, Bot AG, Boomaars WE, Scholte BJ, de Jonge HR (1997) Genistein activates CFTR Cl-channels via a tyrosine kinaseand protein phosphatase-independent mechanism. Am J Physiol 273: C747-53.
12. Galietta LV, Jayaraman S, Verkman AS (2001) Cell-based assay for highthroughput quantitative screening of CFTR chloride transport agonists. Am J Physiol Cell Physiol 281: C1734-1742.
13. Girodon E, Cazeneuve C, Lebargy F, Chinet T, Costes B, Ghanem N, Martin J, Lemay S, Scheid P, Housset B, Bignon J, Goossens M (1997) CFTR gene mutations in adults with disseminated bronchiectasis. Eur J Hum Genet 5: 149-155. (Pubitemid 27356702)
14. Greger R (2000) Role of CFTR in the colon. Annu Rev Physiol 62: 467-491.
15. Haws CM, Nepomuceno IB, Krouse ME,Wakelee H, Law T, Xia Y, Nguyen H, Wine JJ (1996) Delta F508-CFTR channels: kinetics, activation by forskolin, and potentiation by xanthines.AmJ Physiol 270: C1544-1555.
16. HE C, Zhang H, SU Z, Zhou J, Yang H, Ma T (2004) Synthesis and characterization of a small molecule thiazolidinone CFTR chloride channel inhibitor. Chem Res Chinese U 20: 334-337.
17. He Q, Zhu JX, Xing Y, Tsang LL, Yang N, Rowlands DK, ChungYW, Chan HC (2005) Tetramethylpyrazine stimulates cystic fibrosis transmembrane conductance regulator-mediated anion secretion in distal colon of rodents. World J Gastroenterol 11: 4173-4179. (Pubitemid 41086867)
18. Hwang TC, Sheppard DN (1999) Molecular pharmacology of the CFTR Clchannel. Trends Pharmacol 20: 448-453.
19. Hwang TC, Wang F, Yang IC, Reenstra WW (1997) Genistein potentiates wild-type and delta F508-CFTR channel activity. Am J Physiol 273: C988-998. (Pubitemid 27422179)
20. Kunzelmann K (1999) The cystic fibrosis transmembrane conductance regulator and its function in epithelial transport. Rev Physiol Biochem Pharmacol 137: 1-70.
21. Kutuk O, Basaga H (2007) Apoptosis signalling by 4-hydroxynonenal: A role for JNK-c-Jun/AP-1 pathway. Redox Rep 12: 30-34. (Pubitemid 46210351)
22. Ma T, Thiagarajah JR,Yang H, Sonawane ND, Folli C, Galietta LJ,Verkman AS (2002) Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest 110: 1651-1658. (Pubitemid 35424243)
23. Muanprasat C, Sonawane ND, Salinas D,Taddei A, Galietta LJ,VerkmanAS (2004) Discovery of glycine hydrazide pore-occluding CFTR inhibitors: mechanism, structure-activity analysis, and in vivo efficacy. J Gen Physiol 124: 125-137. (Pubitemid 39038187)
24. Pratha VS, Hogan DL, Martensson BA, Bernard J, Zhou R, Isenberg JI (2000) Identification of transport abnormalities in duodenal mucosa and duodenal enterocytes from patients with cystic fibrosis. Gastroenterology 118:1051-1060. (Pubitemid 30346982)
25. Riordan JR (2008) CFTR function and prospects for therapy. Annu Rev Biochem77: 701-726.
26. Riordan JR, Rommens JM, Kerem D, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL,DrummML, Iannuzzi MC, Collins FS, Rsui L (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: 1066-1073. (Pubitemid 19231814)
27. Schultz BD, Singh AK, Devor DC, Bridges RJ (1999) Pharmacology of CFTR chloride channel activity. Physiol Rev 79 (1 Suppl): S109-144. (Pubitemid 29058911)
28. Sheppard DN,WelshMJ(1999) Structure and function of theCFTRchloride channel. Physiol Rev 79(1 Suppl): S23-45.
29. Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK, Lee SS (2001) Molecular mechanisms underlying chemopreventive activities of antiinflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res 480-481: 243-268. (Pubitemid 32744832)
30. Tyagi A, Singh RP, Agarwal C, Siriwardana S, Sclafani RA, Agarwal R (2005) Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATRChk1/ 2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinogenesis 26: 1978-1987. (Pubitemid 41631273)
31. Ulrich S, Wolter F, Stein JM (2005) Molecular mechanisms of the chemopreventive effects of resveratrol and its analogs in carcinogenesis. Mol Nutr Food Res 49: 452-461. (Pubitemid 40780392)
32. Yang H, Shelat AA, Guy RK, Gopinath VS, Ma T, Du K, Lukacs GL, Taddei A, Folli C, Pedemonte N, Galietta LJ, Verkman AS (2003) Nanomolar Affinity Small Molecule Correctors of Defective {Delta}F508-CFTR Chloride Channel Gating. J Biol Chem 278: 35079-35085. (Pubitemid 37102270)
33. Yu J, Chen Z, Ni Y, Li Z (2012) CFTR mutations in men with congenital bilateral absence of the vas deferens (CBAVD): A systemic review and meta-analysis. Hum Reprod 27: 25-35.
34. Zegarra-Moran O, Romio L, Folli C, Caci E, Becq F, Vierfond JM, Mettey Y, Cabrini G, Fanen P, Galietta LJ (2002) Correction of G551D-CFTR transport defect in epithelial monolayers by genistein but not by CPX or MPB-07. Br J Pharmacol. 137: 504-512. (Pubitemid 35221904)